PatientsVille.com Logo

RENAL FAILURE and ACYCLOVIR

PatientsVille

RENAL FAILURE Symptoms and Causes

Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure.

If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of healthcare providers, family, and friends, most people with kidney failure can lead full and active lives.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for RENAL FAILURE

RENAL FAILURE treatment research studies

ACYCLOVIR clinical trials, surveys and public health registries


Find Drug Side Effect reports



ACYCLOVIR Side Effects

Renal Failure Acute (111)
Nausea (55)
Confusional State (53)
Neurotoxicity (52)
Blood Creatinine Increased (51)
Pyrexia (48)
Hallucination, Visual (38)
Herpes Zoster (38)
Vomiting (37)
Pain (37)
Fatigue (36)
Somnolence (36)
Renal Failure (35)
Diarrhoea (34)
Agitation (31)
Rash (31)
Renal Impairment (30)
Dyspnoea (30)
Haemodialysis (28)
Neutropenia (28)
Malaise (27)
Encephalopathy (27)
Febrile Neutropenia (27)
Dysarthria (26)
Hallucination (26)
Platelet Count Decreased (26)
Nephropathy Toxic (26)
Back Pain (24)
Alanine Aminotransferase Increased (23)
Insomnia (23)
Abdominal Pain (23)
Headache (22)
White Blood Cell Count Decreased (22)
Aphasia (22)
Pruritus (21)
Disorientation (20)
Hypertension (19)
Dizziness (19)
Pancytopenia (19)
Abdominal Pain Upper (19)
Coma (19)
Paraesthesia (19)
Pneumonia (18)
Sepsis (18)
Blood Pressure Increased (18)
Hepatotoxicity (17)
Anaemia (17)
Ataxia (17)
Hypotension (17)
Multi-organ Failure (17)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i had heart failure last august 2010, among other tablets i have been taking emconcor. i wonder whether these tablets are responsible for making my limbs feel weak, and lightheaded.

i am taking aprove tab 150 daily becoz of renal failur one year age ,i read about aprovel side effect.i am afried to of side effect. and my b.b in normal rang

<b>Describe Your Tazocin Experience Here:</b>after it was administered to my farther in hospital for the first time on day he was due to be released he had a cardiac arrest with multiple organ failure and subsequently died

had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom

i am from India my father who has been suffering from renal problem. i consulted a nephrology who advised me to take wysolone tab. now my father has been suffering from loose motion(sever loose motion). he can'

A report-I had a suppression dose of Macrobid; after 8 months much worse and after a year in fulminant hepatic failure leading to a transplant. How can these changes be spotted for women like me.

AGGRENOX SIDE EFFECT. PATIENT WAS PRESCRIBED PLAVIX. AGGRENOX WAS SUBSTITUTED. PATIENT SUFFERED ACUTE RESPIRATORY FAILURE AND CARDIO-RESPIRATORY ARREST. PATIENT WAS HOSPITALIZED. PATIENT DIED 3/29/09.

An injection of toradol in hattiesburg Forrest general Hospital resulted in complete Kidney failure with 5 days in hospital. medical records are available if proof is needed. recovered

Been on drug since 1/20/11. er mid feb w/diagnosis of acid reflux; as time went on i have had excessive gas, leg/ankle swelling; loss of appetite; dry cough; sleepiness; lack of energy; out of breath; docs say heart failure---this is an 85 yr old man

Can Aspavor cause itching? If it can cause renal problems, itching is a symptom of this?

RENAL FAILURE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Effect of Body Mass on Acyclovir Pharmacokinetics
Conditions: Hematological Malignancy;   Pharmacokinetics of Acyclovir
Intervention:
Outcome Measures: Systemic clearance of Acyclovir in obese and non-obese patients;   Alpha and beta half-life of Acyclovir in obese and non-obese patients;   Maximum concentration (Cmax) of Acyclovir in obese and non-obese patients;   Time to maximum concentration (Tmax) of Acyclovir in obese and non-obese patients;   Volume of distribution (Vd and Vdss) of Acyclovir in obese and non-obese patients;   Time that concentration is above IC50 for varicella and herpes viruses 4,5,6,7 for Acyclovir in obese and non-obese patients
2 Recruiting Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease
Condition: Meniere's Disease
Interventions: Drug: Acyclovir;   Drug: Placebo
Outcome Measures: Vertigo;   Hearing Loss;   Aural Fullness;   Tinnitus
3 Recruiting Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: Famciclovir;   Drug: Aciclovir
Outcome Measures: For efficacy evaluation, a visual analogue scale (VAS) will be used to detect the improvement of symptoms;   Safety will be evaluated by the adverse events occurrences
4 Recruiting Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
Condition: GENITAL HERPES
Interventions: Drug: Famciclovir;   Drug: Aciclovir
Outcome Measures: Efficacy will be evaluated by the proportion of subjects with non herpes manifestation;   Safety will be evaluated by the Adverse events occurence
5 Recruiting PTH - Preemptive Treatment for Herpesviridae
Condition: Viral Pneumonia
Interventions: Drug: Aciclovir;   Drug: Ganciclovir;   Drug: Placebo
Outcome Measures: Ventilator-free days at Day 60;   Day 60 mortality;   ICU mortality;   Hospital mortality;   Duration of mechanical ventilation in survivors;   Duration of ICU stay;   Duration of hospital stay;   Incidence of ventilator-associated pneumonia;   Incidence of bacteremia;   SOFA score;   Acute renal failure related to aciclovir or its placebo;   Leucopenia related to ganciclovir or its placebo;   Time to oropharyngeal negativation of HSV PCR;   Time to blood negativation of CMV PCR;   Incidence of herpetic bronchopneumonia;   Incidence of active CMV infection
6 Not yet recruiting A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC
Condition: Articular Cartilage Defect
Interventions: Procedure: ACIC;   Procedure: MCIC;   Device: implant with a collagen + fibrin gel mixture
Outcome Measures: Clinical outcome;   Radiological outcome
7 Recruiting Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)
Condition: Obesity
Intervention: Other: Salivary Cortisol
Outcome Measures: Number of patients with positive salivary cortisol dosage among patients with positive serum cortisol dosage;   Number of patients with negative salivary cortisol dosage among patients with negative serum cortisol dosage;   Comparing the results of salivary cortisol dosage and serum cortisol dosage;   Comparing the results of the two salivary samples;   Number of patients with metabolic complications of obesity among patients with ACIC;   Number of patients with severe type 2 diabetes among patients with ACIC
8 Not yet recruiting Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: Foscarnet Sodium;   Drug: Acyclovir
Outcome Measures: Effective rate;   Incidence of Postherpetic neuralgia;   number of participants with adverse event and serious adverse event
9 Recruiting Cytomegalovirus Control in Critical Care
Condition: Critical Illness
Interventions: Drug: Valaciclovir/Aciclovir;   Drug: Valganciclovir/Ganciclovir
Outcome Measures: Time to reactivation of cytomegalovirus (CMV) polymerase chain reaction (PCR) (defined as above the lower limit of sample assay).;   Time to reactivation above the lower limit of assay detection of CMV PCR in urine, throat swab and non-directed bronchiolar lavage (NDBL). NDBL whilst trachea is intubated only.;   Time to >1000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated);   Time to >10000 CMV copies in blood, urine, throat swab and NDBL (NDBL whilst intubated);   CMV PCR in blood, urine, throat swab and NDBL (NDBL whilst intubated);   Markers of inflammation;   Clinical Outcomes;   Number of Serious Adverse events;   Time to neutropenia (count <1.0x10-9/L);   Time to thrombocytopenia (platelet <50x10-9/L);   Use of G-CSF or termination of study drug;   Number of platelet transfusions received;   Time to renal insufficiency (CrCl <60ml/min, <30ml/min, need for renal support)
10 Unknown  Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
Condition: Herpes Simplex
Intervention: Drug: Acyclovir
Outcome Measure:
11 Unknown  Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
Condition: Reccurent Herpes Labialis
Interventions: Drug: Acyclovir 5%;   Drug: Docosanol 10%;   Device: Superlysine gel
Outcome Measure: Reducing healing process and duration of cold sores using superlysin gel
12 Recruiting Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Bortezomib;   Drug: Acyclovir
Outcome Measures: efficacy of single-agent subcutaneous bortezomib;   Efficacy;   Toxicity
13 Recruiting Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Acyclovir
Outcome Measures: Progression-free survival (PFS);   Prostate-Specific Antigen (PSA) changes;   Circulating Tumor Cell (CTC) enumeration;   Baseline whole blood 20S proteasome level;   Measurable disease response rate;   Pain response;   Overall survival;   Assessment of toxicities
14 Not yet recruiting A Multiple Ascending Dose-Finding Pharmacokinetic and Pharmacodynamic Study of a Novel Antiviral Drug in Infants With Neonatal Herpes Simplex Virus (HSV)
Condition: Herpes Simplex Virus
Interventions: Drug: Novel Antiviral Drug;   Drug: Placebo
Outcome Measures: Plasma pharmacokinetic parameters for a Novel Antiviral Drug, including AUC24, maximum serum concentration (Cmax), half-life (T1/2), CL/F, and time to maximum concentration (Tmax);   Clearance of HSV DNA from CSF by Day 4 of antiviral treatment of neonatal HSV disease;   The incidence of SAEs and AEs considered to be related to study treatment;   The incidence of grade 3-4 AEs and SAEs, with or without relationship to study treatment;   Intracellular pharmacokinetic parameters for the active diphosphate moiety of a Novel Antiviral Drug in peripheral blood mononuclear cells (PBMCs);   Correlation of a Novel Antiviral Drug plasma and intracellular concentrations with qualitative and quantitative HSV detection in cerebrospinal fluid and blood by PCR
15 Unknown  Can ValAcyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
Conditions: HIV Infections;   Herpes Simplex
Interventions: Drug: ValAcyclovir;   Drug: Placebo
Outcome Measures: Percentage activated CD8+ T-cells;   Inflammatory markers;   CD4 cell count;   Virologic blips;   Drug-related adverse events;   HSV reactivations;   Acyclovir-resistant HSV
16 Recruiting Can ValAcyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals With Herpes Simplex Virus Type 2?
Conditions: HIV Infection;   Herpesvirus 2, Human;   HIV Infections
Interventions: Drug: valAcyclovir;   Drug: Placebo
Outcome Measures: Time from baseline until reaching the primary endpoint, a composite of either a CD4 cell count ≤350 cells/mm3 measured on two consecutive occasions at least 1 month apart, or initiation of HAART for any reason, whichever occurs first.;   Annual rate of change in CD4 count, calculated as the slope of patients' CD4 count change / time;   Annual rate of change in the CD4 cell count percentage, calculated as the slope of the patient's CD4 count percentage change over time;   Log10 plasma HIV viral load;   Treatment-emergent adverse events and laboratory abnormalities;   Frequency of episodes of HSV reactivations at any anatomic site;   Proportion of microbiologically confirmed flares of HSV during the trial that are caused by laboratory-confirmed Acyclovir-resistant HSV;   Quality of life
17 Not yet recruiting PACT for Individuals With Serious Mental Illness
Condition: Schizophrenia and Disorders With Psychotic Feature
Intervention: Other: Patient Aligned Care Team (PACT)
Outcome Measures: Composite Prevention Score;   Composite Diabetes Mellitus Score;   medical and mental health treatment utilization and cost;   Assess acceptability of the SMI-PACT model, and barriers and facilitators to its implementation;   Investigate the relationships between organizational context, intervention factors, and patient and provider outcomes;   Identify factors related to successful patient outcomes;   VA Decision Support System National Database Extracts (DSS NDEs);   Assessment of Chronic Illness Care (ACIC);   patient Assessment of Chronic Illness Care (PACIC);   Rogers' Adoption Questionnaire;   Maslach Burnout Inventory (MBI);   Behavior and Symptom Identification Scale - Revised (BASIS-R);   Ambulatory Care Experiences Survey (ACES; Short Form);   Interpersonal Support Evaluation List (ISEL);   Medication Possession Ratio (MPR);   Ethnographic field notes;   Semi-structured qualitative interviews
18 Recruiting Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
Condition: Refractory Cold Agglutinin Disease
Intervention: Drug: Bortezomib
Outcome Measures: Number of patients who become transfusion-free after Bortezomib therapy.;   Number of patients who have never been transfused with a >2g hemoglobin rise compared to baseline.;   Number of CTC grade 3 and 4 adverse events.;   Duration in months of transfusion independence.;   Effect of treatment on the underlying clonal B cell disorder.
19 Unknown  Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
Outcome Measure: response rate for induction chemotherapy
20 Recruiting HSV-tk + ValAcyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: HSV-tk +ValAcyclovir in Combination with Brachytherapy
Outcome Measures: 1. Safety based on standard laboratory and clinical adverse event monitoring;   Local control survival (measured by PSA and biopsy);   Evaluate immunological markers